Fundraising Fox

Dominik Escher

Investor

Managing Partner at Pureos Bioventures

Zurich, Switzerland

Writes $100K – $5M checks · typically $1.5M

About

Dominik Escher is a biotechnology entrepreneur who founded ESBATech in 1998 and served as its CEO until 2016, raising over $90 million in venture capital before the company's acquisition by Alcon for $589 million in 2009. Following Alcon's acquisition by Novartis in 2011, he led ESBATech as part of the Novartis Institutes of Biomedical Research, where the company developed antibody fragment therapeutics including Brolucizumab, which received FDA approval for wet age-related macular degeneration in 2019. Escher currently serves as Managing Partner of Pureos Bioventures, Chairman of CDR-Life AG, and Board Member of Adcytherix, and previously served as President of the Swiss Biotech Association from 2013 to 2022.

Contact· self-published, not guessed

Experience

  1. AdcytherixBoard Membercurrent2026 — present
  2. Tavo BiotherapeuticsBoard Membercurrent2026 — present
  3. Botnar Institute of Immune Engineering – BIIEChairman of the Board of Trusteescurrent2024 — presentBasel, Switzerland
  4. Swiss Biotech AssociationHonorary Membercurrent2022 — present
  5. Swiss Biotech AssociationPresident2013 — 2022
  6. Swiss Biotech AssociationBoard member and Vice President2002 — 2013
  7. CDR-Life Inc.Chairmancurrent2017 — presentZurich, Switzerland
  8. Pureos BioventuresManaging Partnercurrent2017 — presentZurich, Switzerland
  9. PulseSight TherapeuticsBoard Membercurrent2020 — presentParis, Fort Worth
  10. NovaGo TherapeuticsBoard of Directorscurrent2019 — presentZurich
  11. Topadur Pharma AGBoard Member2017 — 2026Zurich, Switzerland
  12. Araris Biotech AGBoard Member2020 — 2025Zurich, Switzerland
  13. ESBATech, a Novartis company LLCHead ESBATech2009 — 2016
  14. ESBATech, a Novartis company LLCCEO1998 — 2009

Skills & more

Immunology13Molecular Biology15Biochemistry12Biotechnology31Lifesciences12Drug Discovery32Clinical Development18Pharmaceutical Industry12Drug Development13Clinical Trials9Clinical Research5Biopharmaceuticals39
+8 moreLife SciencesOncologyCommercializationPatentsCROTechnology TransferPharmacologyProtein Chemistry

From Dominik's professional profile.

Colleagues at Pureos Bioventures

Anne Grahl
Associate at Pureos Bioventures
Butrint Aliu
Analyst at Pureos Bioventures
Christian Altorfer
CFO/COO at Pureos Bioventures
Dragan Grabulovski
Venture Partner at Pureos Bioventures
Klaus Breiner
Managing Partner at Pureos Bioventures
Lars Nieba
Venture Partner at Pureos Bioventures
Martin Münchbach
Managing Partner at Pureos Bioventures
Veronica Gambillara Fonck
Partner at Pureos Bioventures

Network5

Anne Grahl
Associate at Pureos Bioventures
Dragan Grabulovski
Venture Partner at Pureos Bioventures
Klaus Breiner
Managing Partner at Pureos Bioventures
Lars Nieba
Venture Partner at Pureos Bioventures
Luigi Costa
Investor at Pureos Bioventures

Investors connected to Dominik in public investor directories — a warm-intro map.

Frequently asked questions

Who is Dominik Escher?
Dominik Escher is a biotechnology entrepreneur who founded ESBATech in 1998 and served as its CEO until 2016, raising over $90 million in venture capital before the company's acquisition by Alcon for $589 million in 2009. Following Alcon's acquisition by Novartis in 2011, he led ESBATech as part of the Novartis Institutes of Biomedical Research, where the company developed antibody fragment therapeutics including Brolucizumab, which received FDA approval for wet age-related macular degeneration in 2019. Escher currently serves as Managing Partner of Pureos Bioventures, Chairman of CDR-Life AG, and Board Member of Adcytherix, and previously served as President of the Swiss Biotech Association from 2013 to 2022.
Where does Dominik Escher work?
Dominik Escher is Managing Partner at Pureos Bioventures.
What check size does Dominik Escher write?
Dominik Escher typically writes checks of $100K – $5M.
Where did Dominik Escher go to school?
Dominik Escher studied at University of Zurich (Ph.D., Molecular Biology); University of California, San Francisco (Molecular Biology); University of Zurich (M.S., Molecular Biology).

Same school

Also attended University of Zurich76

Christoph FreiPartner, Head of Energy at Emerald Technology Ventures AgAndy WeymannVenture Partner, Frontiers in Health & Bio Investments at Verve VenturesDavid FischerInvestor at FELIX CAPITALJohannes ClaussSerial Entrepreneur, Investor and Mentor at tokentus investment AGMartin ScherrerPartner & Head of Managed Funds at RedstonePatrik BrudererCFO at CV Labs

+ 70 more

Also attended University of California, San Francisco67

Douglas CrawfordManaging General Partner at Mission BiocapitalLuke EvninAdvisor at MPM BioImpactCharles White, Ph.D.Principal at Illumina VenturesMatt MaurerInvestor at WVV CapitalAlec NielsenFounder & CEO, Asimov & Venture Partner at Pillar VCYvanka de SoysaAssociate at Foreground Capital

+ 61 more

Also attended ETH Zürich225

Bastian HasslingerInvestor at Index VenturesSteve VassalloInvestor at Foundation CapitalHelge DaebelPartner, Head of Water at Emerald Technology Ventures AgMaurin DaiInvestment Manager, Physical AI & Robotics at Emerald Technology Ventures AgChristoph FreiPartner, Head of Energy at Emerald Technology Ventures AgMax HeftiInvestment Director - Energy at Emerald Technology Ventures Ag

+ 219 more

Shared employers

Also worked at Adcytherix2

Ximing DingInvestment Manager at Pureos BioventuresXavier PrevilleCo-founder, VP & Head of Research & Preclinical Development at Adcytherix

Also worked at Tavo Biotherapeutics2

Butrint AliuAnalyst at Pureos BioventuresDaniel BradburyInvestor at BioBrit

Also worked at CDR-Life Inc.1

Dan MarksPrincipal at RA Capital

Also worked at PulseSight Therapeutics1

Anne GrahlAssociate at Pureos Bioventures